Abstract. Several studies have shown that microRNA-375 (miR-375) is frequently downregulated in several types of human cancer including gastric cancer, colorectal cancer and oral squamous cell carcinoma. However, the role of miR-375 in human esophageal cancer remains unknown. In the current study, the expression level of miR-375 was analyzed in 43 esophageal squamous cell carcinoma (ESCC) tissue and matched adjacent normal tissue samples from patients with ESCC by reverse transcription-quantitative polymerase chain reaction. In addition, the expression level of miR-375 was analyzed in ESCC cell lines (KYSE450 and KYSE150) and the human esophageal epithelial cell line Het-1A by the same method. The expression level of miR-375 was significantly downregulated in ESCC tissue samples and cell lines compared with adjacent normal tissue samples and the human esophageal epithelial cell line, respectively. The effect of miR-375 on ESCC cell proliferation was detected by cell counting kit-8 (CCK-8) and colony formation assays. miR-375 overexpression significantly decreased ESCC cell proliferation and colony formation. Bioinformatics analysis was used to predict specificity protein 1 (SP1) as a target gene of miR-375 in ESCC, and this was verified by dual-luciferase assay. The present study demonstrated that SP1 regulates ESCC cell proliferation and colony formation through direct interaction with miR-375. In addition, the overall survival of patients with ESCC was analyzed using the Kaplan-Meier method and log-rank test. The results indicated that patients with ESCC with high miR-375 expression had a better survival rate compared with patients with ESCC with low miR-375 expression. Taken together, these results suggest that downregulated miR-375 promotes ESCC cell proliferation and colony formation via direct targeting of SP1, and this association may contribute to ESCC progression.
Introduction
Esophageal cancer (EC) is one of the most commonly diagnosed types of cancer and it is the sixth leading cause of cancer-associated mortality worldwide (1) . Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EA) are the two major histological subtypes of EC (2, 3) . EA has become the leading histological subtype of EC, corresponding to a rise in North America and Western Europe (4) . ESCC remains the predominant histological subtype in developing countries in East Asia and Africa (5, 6) . In China, more than 90% of all EC cases are ESCC, increasing the economic burden to the whole country (7, 8) . Large population-based studies have revealed that early diagnosis methods can increase the overall survival rates of ESCC (9, 10) . Therefore, investigating the underlying mechanism associated with ESCC progression is necessary for improvement in the overall survival of patients with ESCC.
MicroRNAs (miRNAs) are a class of non-coding, single-stranded RNA molecules that can promote mRNA degradation or inhibit mRNA translation by binding to complementary sites in the 3'untranslated region (3'UTR) of mRNAs (11) . Previous studies have revealed that miRNAs are involved in multiple cellular processes, including cell proliferation (12) , cell cycle (13) and cell apoptosis (14) . Furthermore, there is growing evidence to support the association between miRNA dysregulation and human diseases (12) (13) (14) (15) (16) , including the occurrence and progression of several types of cancer (12) (13) (14) . Several studies have demonstrated that miRNAs may be involved in ESCC progression and prognosis (17) (18) (19) . microRNA-375 (miR-375) was initially identified in pancreatic islet cells and its overexpression suppressed glucose-induced insulin secretion (20) . miR-375 is downregulated in several types of cancer, acting as a tumor suppressor (21, 22) . The expression pattern and biological function of miR-375 in ESCC remains largely unknown. Previous studies have identified a number of downstream target genes of miR-375 associated in several types of cancer (22, 23) . Wang et al (23) revealed that miR-375 was downregulated in squamous cervical cancer and inhibited cell migration and invasion by targeting specificity protein 1 (SP1). SP1 is a transcription factor that serves a role in the regulation
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HUI XU 1, 2 , JIALONG JIANG 1 , JINGJUN ZHANG 2 , LIANG CHENG of tumor survival, progression and metastasis (24, 25) . High SP1 expression was identified in several types of cancer and was associated with poor prognosis (23, (26) (27) (28) . However, it is not known whether SP1 is involved in regulating ESCC cell proliferation. The current study demonstrated that miR-375 was downregulated in ESCC tissue samples. The role of miR-375 in ESCC cell proliferation and colony formation was investigated. The present study revealed that knockdown of miR-375 significantly increased ESCC cell proliferation and colony formation. Furthermore, SP1 was identified as a direct target gene of miR-375 in ESCC. The results suggest that miR-375 may act as a tumor suppressor, and therefore miR-375 may be a potential therapeutic target for ESCC.
Patients and methods
Patient samples. The present study analyzed tissue samples from patients diagnosed with ESCC. A total of 43 ESCC (23 males and 20 females; age range, 41-79 years old) tissue and matched adjacent normal tissue samples were collected from patients who had undergone surgical resection at The First Affiliated Hospital of Anhui Medical University (Hefei, China) between June 2008 and April 2010. All tissue samples were stored at -80˚C. None of the patients received any treatment prior to surgery. The current study was approved by the Ethics Committee of The First Affiliated Hospital of Anhui Medical University (Hefei, China). Written informed consent was obtained from all the patients. The clinicopathological features of these patients are summarized in Table I .
Cell culture. ESCC cell lines KYSE450 and KYSE150, as well as the human normal esophageal epithelial cell line Het-1A were purchased from Shanghai Gaining Biotechnology Co., Ltd. (Shanghai, China). Cells were cultured in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.) and maintained at 37˚C and in a 5% CO 2 -humidified incubator.
Cell transfection. miR-375 mimic (5'-UUU GUU CGU UCG GCU CGC GUG A-3'), miR-375 inhibitor (5'-UCA CGC GAG CCG AAC GAA CAA A-3'), and negative control (NC) miRNAs (NC mimic: 5'-GCG UGC UUC CGA UUG UUC UGU G-3'; NC inhibitor: 5'-GCG ACA ACA AUA AGA CCG ACG C-3'), as well as the SP1 siRNA (5'-AAG ATC ACT CCA TGG ATG AAA-3') and NC siRNA (5'-ACA CGA CAA TTC GAA GAA TTG-3') were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The SP1 open reading frame that cloned into pcDNA3.1 using Hind III/BamH I restriction enzymes was purchased from GenScript Biotech Corp. (Nanjing, China). KYSE450 and KYSE150 cells were seeded in six-well plates at a density of 3x10 5 cells/well in RPMI-1640 medium and grown for 24 h. Cells were subsequently transfected with 100 nM miR-375 mimic, inhibitor, NC miRNA, SP1 siRNA or NC siRNA using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Following a 48 h transfection, cells were collected for following assays.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA, containing miRNA, was extracted from tissue samples and KYSE450, KYSE150 and Het-1A cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The quantity and purity of RNA were measured using a NanoDrop spectrophotometer (ND-1000; Nanodrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). To detect the expression level of miR-375, total RNA was reverse transcribed into Table I . Association between miR-375 expression status and clinicopathological characteristics of patients with ESCC. cDNA using a specific reverse-transcription primer (5'-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CAC GC-3') by PrimeScript™ II 1st Strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. qPCR was subsequently performed using TaqMan™ Fast Advanced Master mix (Thermo Fisher Scientific, Inc.) with the following thermocycling conditions: 95˚C for 20 sec, followed by 40 cycles of 95˚C for 3 sec and 60˚C for 30 sec. The primer specific probes purchased from Applied Biosystems (Thermo Fisher Scientific, Inc.; Table II ). miR-375 expression levels were normalized to the internal reference gene U6 small nuclear RNA using the method of 2 -ΔΔCq method (29). To detect the expression level of SP1, total RNA was reverse transcribed into cDNA using the cDNA First Strand Synthesis kit (Beyotime Institute of Biotechnology, Haimen, China). qPCR was subsequently performed using the BeyoFast™ SYBR ® -Green PCR Master mix (Beyotime Institute of Biotechnology) on the Applied Biosystems ® 7500 Sequence Detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the following thermocycling conditions: 95˚C for 10 min, followed by 45 cycles of 95˚C for 15 sec, 60˚C for 30 sec. The following primer pairs were used for the qPCR: SP1 forward, 5'-GGC TCG GGG GAT CCT GGC-3' and reverse, 5'-TAT GGC CCA TAT GTC TCT G-3'; and EEF1A1 forward, 5'-TGC GGT GGG TGT CAT CAA A-3' and reverse, 5'-AAG AGT GGG GTG GCA GGT ATT G-3'. The SP1 mRNA levels were quantified using the 2 -ΔΔCq method and normalized to the internal reference gene EEF1A1. Each experiment was performed in triplicate.
Western blot analysis. Total protein was extracted from KYSE450, KYSE150 and Het-1A cells using RIPA lysis buffer (Beyotime Institute of Biotechnology) 48 h post-transfection. Total protein was quantified using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology) and proteins (50 µg/lane) were separated via SDS-PAGE on a 10% gel. The separated proteins were subsequently transferred onto nitrocellulose membranes (EMD Millipore, Billerica, MA, USA) and blocked for 2 h at room temperature with 5% skimmed milk. The membranes were incubated with primary antibodies against SP1 (1:200; cat. no. SC-420) and GAPDH (1:1,000; cat. no. SC-47724; both from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4˚C. Following primary incubation, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:1,000; cat. no. A0216; Beyotime Institute of Biotechnology) at room temperature for 1 h. Protein bands were visualized using BeyoECL Plus kit (Beyotime Institute of Biotechnology) and protein expression was quantified using ImageJ2x software (National Institutes of Health, Bethesda, MD, USA).
Cell proliferation assay. Cell proliferation was analyzed using the CCK-8 (Beyotime Institute of Biotechnology), according to the manufacturer's protocol. Cells were seeded into 96-well plates at a density of 2x10 4 cells/well and cultured for 0, 24, 48 and 72 h, after which 10 µl CCK-8 reagent was added to each well. Cells were further incubated at 37˚C for 2 h. Absorbance was measured at a wavelength of 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each experiment was performed in triplicate.
Colony formation assay. Cells were seeded into six-well plates at a density of 1x10 3 cells/well and cultured for two weeks. Subsequently, cells were fixed with 4% paraformaldehyde at room temperature for 15 min and stained with 0.05% crystal violet at room temperature for 20 min. Colony formation was observed and images were captured using a BX53 light microscope (Olympus Corporation, Tokyo, Japan) equipped with a MicroPublisher 3.3RTV camera (Quantitative Imaging Corporation, Surrey, BC, Canada).
Dual-luciferase reporter assay. The targets of the miR-375 were predicted using the bioinformatic algorithm software TargetScan v7.2 (http://www.targetscan.org/vert_72/). The wild-type (wt) 3'UTR of SP1 was amplified and cloned into pmirGLO vector (Promega Corporation, Madison, WI, USA). Site-directed gene mutagenesis was performed to generate the mutant-type (mut) 3'UTR-SP1 using a Site-Directed Mutagenesis kit (Takara Biotechnology Co., Ltd.). KYSE450 and KYSE150 cells were seeded into 96-well plates (3x10 5 cells/well) and co-transfected with 100 nM miR-375 mimic (or NC miRNA) and 3'UTR-SP1 (or 3'UTR-SP1 mut) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Following incubation for 48 h, luciferase activity was detected using a Dual-Luciferase ® Reporter Assay system (Promega Corporation) according to the manufacturer's protocol and (Fig. 1A) . Similarly, the expression level of miR-375 was significantly decreased in ESCC cell lines KYSE450 and KYSE150, compared with normal esophageal endothelial cell line Het-1A (Fig. 1B) . These results suggest that downregulation of miR-375 may be associated with the pathogenesis of ESCC.
Overexpression of miR-375 inhibits ESCC cell proliferation and colony formation.
To investigate the role of miR-375 in ESCC progression, ESCC cell lines KYSE450 and KYSE150 were transfected with miR-375 mimic, inhibitor or negative controls and the miR-375 expression level was detected by RT-qPCR. The results demonstrated that the miR-375 mimic significantly increased miR-375 expression in both KYSE450 and KYSE150 cell lines, whilst the miR-375 inhibitor significantly decreased miR-375 expression in both ESCC cell lines (Fig. 2A) . CCK-8 assays demonstrated that the cell proliferation rate was significantly increased in ESCC cells compared with normal esophageal endothelial cells (Fig. 2B) . In addition, the colony formation ability of ESCC cells increased compared with normal esophageal endothelial cells (Fig. 2C) . Furthermore, CCK-8 assays demonstrated that miR-375 overexpression inhibited the proliferative ability of ESCC cells compared with the negative control, whilst downregulation of miR-375 expression had the opposite effect (Fig. 2D) . Similar results were obtained in the colony formation assays, miR-375 overexpression inhibited colony formation in ESCC cells, whilst downregulation of miR-375 expression induced the opposite effect (Fig. 2E) . These results suggest that miR-375 overexpression inhibits ESCC cell proliferation and colony formation.
SP1 is a novel target gene of miR-375.
To further investigate the role of miR-375 in ESCC progression, potential targets of miR-375 in ESCC were examined. TargetScan v7.2 software was used to identify SP1 as a putative target gene of miR-375 (Fig. 3A) , and this was verified by dual-luciferase assay. Following co-transfection with miR-375 mimic, the luciferase reporter activity of 3'UTR-SP1 was significantly reduced compared with 3'UTR-SP1 3'mut (Fig. 3B) . In addition, co-transfection with NC miRNA had no effect on luciferase activity. The protein expression level of SP1 was significantly increased in ESCC tissue samples compared with matched adjacent healthy tissue samples from patients with ESCC (Fig. 3C) . Similarly, the protein expression levels of SP1 were significantly increased in ESCC cell lines KYSE450 and KYSE150, compared with normal esophageal endothelial cell line Het-1A (Fig. 3D) . Furthermore, the protein expression level of SP1 was significantly decreased following overexpression of miR-375 in the ESCC cell line KYSE450 (Fig. 3E) . Additionally, an inverse correlation was observed between miR-375 and SP1 expression in ESCC (Fig. 3F) , which further confirmed SP1 as a target gene of miR-375.
SP1 regulates cell proliferation and colony formation through miR-375.
To further investigate the association between miR-375 and SP1, the functional role of SP1 in miR-375-induced cell proliferation and colony formation inhibition was examined. The mRNA and protein expression levels of SP1 were significantly decreased in ESCC cell line KYSE450 following transfection with SP1-siRNA, whilst the mRNA and protein expression levels of SP1 were significantly increased following transfection with SP1 construct (Fig. 4A and B) . In addition, downregulation of SP1 expression inhibited KYSE450 cell proliferation and colony formation, whilst overexpression of SP1 had the opposite effect, consistent with the effects of miR-375 on ESCC cell proliferation and colony formation (Fig. 4C and D) . Furthermore, rescue experiments demonstrated that SP1 significantly reversed the inhibitory effects of miR-375 on ESCC cell proliferation and colony formation (Fig. 4C and D) .
Clinical significance of miR-375 expression in ESCC.
The clinical significance of miR-375 expression in ESCC was examined. According to the expression level of miR-375, patients with ESCC were divided into two groups: high miR-375 expression and low miR-375 expression. The 75th percentile of miR-375 expression level was used as a cut-off point (30) . The association between miR-375 expression and the clinicopathological features were examined (Table I) . The low miR-375 expression group was associated with advanced tumor staging, however no association with sex, age or tumor size was identified (Table I) . Furthermore, the overall survival analysis demonstrated that patients with ESCC with high miR-375 expression had a better 5-year survival rate compared with patients with ESCC with low miR-375 expression (Fig. 5) . In addition, univariate and multivariate analysis identified miR-375 expression and tumor staging as independent factors, which may be used to predict the prognosis of patients with ESCC (Table III) . of several molecular pathways (12) (13) (14) (15) (16) (17) (18) (19) . Multiple miRNAs have been identified as potential diagnostic and prognostic biomarkers in ESCC (17) . ESCC is associated with poor prognosis among gastrointestinal malignancies (2-4), and it is therefore important to investigate early disease detection methods to improve the overall survival quality of patients with ESCC.
In the current study, miR-375 expression levels in ESCC tissue samples and ESCC cell lines were analyzed. ESCC cell lines KYSE450 and KYSE150 are typically used for studying gene function in vitro (31) . The current study demonstrated that the expression level of miR-375 was significantly decreased in ESCC tissue samples and both ESCC cell lines, which is consistent with recently published data (32) . Furthermore, overexpression of miR-375 suppressed ESCC cell proliferation and colony formation, whereas knockdown of miR-375 promoted ESCC cell proliferation and colony formation. Taken together, the results suggest that miR-375 may act as a tumor suppressor in ESCC. Studies have identified miR-375 target genes involved in several types of human cancer, which have been used to understand more about the underlying molecular mechanism of miR-375 in tumor progression (22, 23, 32) . TargetScan software was used to identify a conserved binding site for miR-375 in the 3'-UTR of SP1. SP1 regulates the expression of oncogenes and tumor suppressor genes, as well as genes involved in regulatory processes (33) . Dual-luciferase assays were performed to verify the predicted association between miR-375 and SP1. Luciferase reporter activity of cells transfected with 3'UTR-SP1 was significantly reduced compared with 3'UTR-SP1 mut, which suggests that SP1 is a direct target of miR-375 in ESCC. To investigate further the association between miR-375 and SP1, the mRNA and protein expression levels of SP1 were analyzed in ESCC cell line KYSE450 transfected with miR-375 mimic. An inverse correlation was observed between miR-375 and SP1 expression in ESCC cells. Although the protein expression level of SP1 was analyzed using ESCC tissue samples, the expression location of SP1 in tissues using immunofluorescence and immunohistochemistry studies needs further investigation. To investigate whether SP1 was a functional target of miR-375, the mRNA and protein expression levels of SP1 were analyzed in ESCC cell line KYSE450 transfected with siRNA targeting SP1. Downregulation of SP1 inhibited ESCC cell proliferation and colony formation. Taken together, these results suggest that overexpression of miR-375 can inhibit ESCC cell proliferation and colony formation partly through the regulation of SP1 expression. Previous studies have demonstrated that SP1 regulates the expression of its target genes, including miR-205 and nuclear factor-κB, to exert functional roles in tumor progression (34, 35) . To understand the role of miR-375 in ESCC, it is therefore important to identify downstream target genes involved in ESCC progression. The present study revealed that miR-375 may be involved in ESCC progression, and miR-375 may therefore be a potential therapeutic target for ESCC.
Furthermore, the current study also examined the clinical significance of miR-375 expression in patients with ESCC. Low miR-375 expression was associated with advanced tumor staging, suggesting that miR-375 expression may be important in ESCC tumor progression. The overall survival analysis indicated that low miR-375 expression predicts poor prognosis in patients with ESCC. In addition, multivariate analysis identified miR-375 expression and tumor stage as independent factors for the prognosis of patients with ESCC.
In conclusion, miR-375 expression was downregulated in ESCC tissue samples, and associated with tumor stage. SP1 was identified as a direct target of miR-375 and overexpression of miR-375 efficiently suppressed SP1 expression, indicating miR-375 as a potential target for anticancer therapy.
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